Appistry Launches Cloud-Based System for Patient-Centered Translational Research
MOUNTAIN VIEW, CA (January 26, 2015) – Appistry, Inc., a leading provider of tools, software, and services that enable healthcare institutions to practice genomically enhanced medicine, today launched a cloud-based system for conducting patient-centered translational research. Appistry CloudDxSM Translational meets a critical need in clinical research centers: centralizing and coordinating data, processes, and communication in order to leverage institutional expertise and deliver high-quality results to patients and the research community.
In his talk at the Personalized Medicine World Conference in Mountain View, CA, today, Appistry Chief Medical Officer Dr. Cornelius F. Boerkoel described the need for a “communal” effort to combat disease. “Today, we have a broad range of tools for measuring and describing the loss of evolutionary homeostasis—all of the techniques available for studying the genome through next generation sequencing,” Boerkoel said. “But we’ll have achieved truly individualized medicine when we can integrate measures of developmental and physiological homeostasis. A system like CloudDx Translational lays the groundwork for that type of integration.”
CloudDx Translational enables clinical research centers engaged in the study of human disease to build a personalized medicine framework for organizing research activities. All project information is tied to individual patients—including clinical observations, research activities, reporting of results, and deposition of appropriate findings into the public domain. CloudDx Translational integrates the various tasks needed to perform translational research, provides expert systems to facilitate the work of project team members, and ensures that valuable data and insights are searchable and shareable to inform hypothesis generation and decision-making, while holding patient identifiable information secure in accordance with ethical practices of human-subject research.
CloudDx Translational is based on a translational research system developed by the National Institutes of Health Undiagnosed Diseases Program (NIH UDP) in conjunction with Appistry, RURO, Inc., and other partners.
“This combined solution delivers targeted informatics to support translational medicine,” said Tom Dolan, chief operating officer at RURO, Inc. “The system at the NIH UDP has decreased the time required to locate information and orient on history, while providing communication and project tools that have led to more thorough collaborations. We believe that this solution will remove a lot of wasted effort at similar organizations as they explore the genetic causes of human disease.”
CloudDx Translational extends Appistry’s CloudDx product line, launched in June 2014. The original Appistry CloudDx, now renamed CloudDx Clinical, is a cloud service that supports delivery of NGS-based testing by healthcare organizations.
“Both CloudDx solutions have at their core a keen understanding of the complex workflows that must be managed and facilitated to put patients at the center of care, whether it be a research project or a genomic test,” said Kevin Haar, chief executive officer at Appistry. “CloudDx Translational and CloudDx Clinical are very different products, because they are designed to meet the needs of different users. Yet they share a connection to using the cloud to minimize overhead and help institutions gain the capabilities they need to deliver value-added services based on genomics—what we call genomically enhanced medicine.”
Appistry will demonstrate CloudDx Translational at PMWC this week and is hosting a webinar on February 10, 2015. For more information, visit appistry.com/gem.
About Appistry
Appistry, Inc., is helping clinical labs, research institutions, and hospitals practice genomically enhanced medicine by creating world-class bioinformatics tools, cloud services, and software that streamline the analysis of next-generation sequencing data and make genomics data easier to researchers and clinicians to act on. Learn more by connecting with Appistry on Facebook, Twitter and LinkedIn.